acsf2 Antibody

What is ACSF2 and what significance does it have in cellular metabolism?

ACSF2 is an acyl-CoA synthetase that activates fatty acids to their CoA derivatives, playing an essential role in fatty acid metabolism. Unlike other characterized ACS family members, ACSF2 is phylogenetically distinct from known families of short-chain, medium-chain, long-chain, very long-chain, and bubblegum ACSs . Functionally, ACSF2 preferentially activates medium-chain fatty acids containing 6 to 10 carbons, with a Km(app) for C10:0 of 24.4 μM and Vmax(app) of 385 nmol/20min/mg in COS cell protein . The enzyme contributes significantly to cellular metabolism by enabling the incorporation of medium-chain fatty acids into metabolic pathways.

What is the tissue and subcellular distribution pattern of ACSF2?

This differential localization suggests tissue-specific functions for ACSF2 in different cellular compartments .

What are the typical applications for ACSF2 antibodies in research?

ACSF2 antibodies are versatile tools for multiple research applications:

The choice of application depends on the specific research question and experimental design .

How can I validate the specificity of an ACSF2 antibody for my particular experimental system?

Validating antibody specificity is crucial for reliable research results. For ACSF2 antibodies, consider implementing these methodological approaches:

• Knockdown/knockout validation: Generate ACSF2 knockdown cells using siRNA (5'-AAGCGAGCCATGGCTGTCTATCCTGTCTC-3') or shRNA constructs as described in the literature . Compare antibody detection in control versus knockdown samples.

• Overexpression systems: Express tagged ACSF2 in your cell system and verify co-localization with the antibody signal.

• Western blot analysis: Look for a single band at the expected molecular weight (68 kDa theoretical, often observed at 55-70 kDa) .

• Multiple antibody approach: Use antibodies targeting different epitopes of ACSF2 (N-terminal, C-terminal, internal regions) to confirm consistent detection .

• Cross-reactivity testing: In multi-species studies, verify the predicted reactivity (e.g., human: 100%, mouse: 86%, rat: 86%) experimentally in your samples.

These validation steps should be performed in your specific experimental system to ensure reliable results.

What methodological approaches should be considered when studying ACSF2's role in neuronal differentiation?

When investigating ACSF2's role in neuronal differentiation, consider these approaches based on published methodologies:

• Neuro2a differentiation model: Induce differentiation with retinoic acid in control and ACSF2-knockdown Neuro2a cells. Retinoic acid treatment induces neurite outgrowth in these cells, and ACSF2-deficient Neuro2a cells show significantly blunted neurite outgrowth in response .

• Co-localization studies: During differentiation, ACSF2 migrates to nodes and points of neurite-neurite contact along with presynaptic markers like synaptophysin . Use dual immunofluorescence to track this process.

• Stable knockdown approach: Generate stable ACSF2 knockdown cell lines using shRNA in pSilencer 4.1 CMV-Hygro vector with Hygromycin (300 mg/ml) selection for two weeks .

• Cytoskeletal dynamics assessment: Since ACSF2 localization is disrupted by nocodazole (20 μM) treatment, which affects microtubule organization, include cytoskeletal markers in your analysis .

• Enzymatic activity measurement: Assess medium-chain acyl-CoA synthetase activity in differentiating versus undifferentiated cells to correlate with ACSF2 expression levels.

These approaches provide a comprehensive framework for investigating ACSF2's functional role in neuronal differentiation.

How does site-directed mutagenesis of ACSF2 affect its enzymatic activity, and how can this be studied?

Site-directed mutagenesis studies have revealed critical residues for ACSF2 function that can be further investigated:

• Critical lysine residue: Mutation of lysine 599 to alanine abolishes ACSF2 enzyme activity . This residue is evolutionarily conserved and critical for catalytic function.

• Mutagenesis protocol: Use the overlap extension method as described in the literature, where full-length ACSF2 cDNA serves as a template to amplify overlapping fragments incorporating the desired mutation . The primers used for K599A mutation were:

  • Forward primer: 5'-AAATTTGGATCCAGAGCCATGGCTGTCTATCAC-3'

  • Reverse primer 1: 5'-GAATTTCTGGATGGCTCCTGAGATGGT-3'

  • Forward primer 2: 5'-ACCATCTCAGGAGCCATCCAGAAATTC-3'

  • Reverse primer 2: 5'-TTTAAACTCGAGACCCTCCTTTGCTTCACAGT-3'

• Enzymatic assay: Measure activity using COS-1 cell overexpression systems and assess the activation of saturated fatty acids containing 6 to 10 carbons .

• Structure-function analysis: Compare the catalytic domain of ACSF2 with bacterial short-chain ACSs to identify other potentially important residues.

• Subcellular localization assessment: Determine if mutations affect not only activity but also the protein's subcellular localization using immunofluorescence.

This approach enables a detailed understanding of ACSF2's structure-function relationship.

What are the optimal fixation and permeabilization conditions for ACSF2 immunofluorescence studies?

For optimal ACSF2 detection by immunofluorescence:

• Fixation: Use 3% formaldehyde in PBS for 10 minutes at room temperature, as this effectively preserves ACSF2 epitopes while maintaining cellular architecture .

• Permeabilization: When studying Golgi-localized ACSF2 (as in Neuro2a cells), gentle permeabilization is crucial. Consider using 0.1-0.2% Triton X-100 or 0.02-0.05% saponin to maintain Golgi structure.

• Antibody dilution: For immunofluorescence applications, use ACSF2 antibodies at dilutions of 1:20-1:200, optimizing based on your specific antibody and cell type .

• Counterstaining: Include appropriate markers for subcellular compartments (Golgi or mitochondria) to confirm ACSF2 localization. For nuclear visualization, Hoechst staining is recommended .

• Controls: Include ACSF2 knockdown cells as negative controls to confirm antibody specificity.

These conditions should be optimized for each cell type due to the differential subcellular localization of ACSF2 across cell types.

How should western blot protocols be optimized for sensitive and specific detection of ACSF2?

For optimal western blot detection of ACSF2:

• Sample preparation: Due to ACSF2's different subcellular localizations, optimize protein extraction protocols accordingly. For mitochondrial ACSF2, ensure mitochondrial fractions are adequately represented.

• Gel percentage: Use 8-10% polyacrylamide gels to effectively resolve the 68 kDa ACSF2 protein.

• Transfer conditions: For optimal transfer of this medium-sized protein, use semi-dry transfer at 25V for 30 minutes or wet transfer at 100V for 1 hour.

• Blocking: Block membranes with 5% non-fat dry milk in TBST for 1 hour at room temperature.

• Antibody dilution: Use primary ACSF2 antibodies at 1:500-1:1000 dilution in blocking buffer. For enhanced validation antibodies, use 0.04-0.4 μg/mL .

• Detection method: ECL-based detection systems provide sufficient sensitivity for ACSF2 detection in most samples.

• Size verification: Verify the observed molecular weight is between 55-70 kDa, which is the typical range for ACSF2 .

What is the recommended approach for generating stable ACSF2 knockdown cell lines?

Based on published methodologies, the following approach is recommended for generating stable ACSF2 knockdown cell lines:

• shRNA design: Design shRNA sequences targeting the coding sequence of ACSF2. The validated sequence targeting bp 8-27 of the mouse ACSF2 coding sequence is:

  • 5'-AAGCGAGCCATGGCTGTCTATCCTGTCTC-3'

• Vector selection: Insert the shRNA-generating sequence into an appropriate vector such as pSilencer 4.1 CMV-Hygro vector .

• Transfection: Transfect the plasmid into your target cell line (e.g., Neuro2a cells) using an appropriate transfection reagent.

• Selection: Select stable transfectants using Hygromycin (300 mg/ml) for approximately two weeks .

• Clonal isolation: After selection, isolate and expand antibiotic-resistant colonies.

• Validation: Confirm ACSF2 knockdown by both:

  • Indirect immunofluorescence

  • Western blot analysis

• Control line: Generate a control cell line using a random shRNA sequence inserted into the same vector .

This approach allows for long-term studies of ACSF2 function without the transient effects associated with siRNA transfection.

How can ACSF2 antibodies be used to investigate the protein's role in adipocyte differentiation?

ACSF2 plays a role in adipocyte differentiation , which can be investigated using these methodological approaches:

• Temporal expression analysis: Track ACSF2 expression during different stages of adipocyte differentiation using western blotting and qPCR.

• Co-localization studies: Use dual immunofluorescence to examine ACSF2 localization with adipocyte markers during differentiation.

• Functional knockdown: Utilize ACSF2 knockdown approaches in pre-adipocyte models to assess effects on differentiation markers and lipid accumulation.

• Metabolic profiling: Compare medium-chain fatty acid metabolism in control versus ACSF2-deficient adipocytes using labeled fatty acid tracers.

• Protein-protein interactions: Investigate interactions between ACSF2 and PPARγ, as ACSF2 is also known as "PPARG binding, long chain fatty acid acyl Co-A ligase like" , using co-immunoprecipitation with ACSF2 antibodies.

• Enzymatic activity correlation: Correlate ACSF2 enzymatic activity with lipid droplet formation during adipogenesis.

These approaches provide a comprehensive framework for investigating ACSF2's role in adipocyte biology.

What methodological considerations are important when using ACSF2 antibodies for immunohistochemistry in different tissue types?

When performing immunohistochemistry with ACSF2 antibodies across different tissue types, consider:

• Antigen retrieval optimization: For human colon cancer and skin tissues, TE buffer pH 9.0 is recommended, though citrate buffer pH 6.0 may also be effective .

• Dilution optimization: Use ACSF2 antibodies at 1:200-1:800 dilution for IHC applications , but optimize for each tissue type.

• Tissue-specific controls: Include tissue-specific positive and negative controls, as ACSF2 expression varies significantly between cell types within tissues .

• Detection systems: For lower expression tissues, consider using amplification systems such as tyramide signal amplification.

• Counterstaining: Use appropriate counterstains to identify relevant cell types within complex tissues.

• Dual staining: Consider dual staining with cell-type specific markers to accurately identify ACSF2-expressing cells within heterogeneous tissues.

• Validation approach: Validate antibody specificity using multiple ACSF2 antibodies targeting different epitopes .

This methodological approach accounts for the variable expression and subcellular localization of ACSF2 across different tissues.

What are common issues encountered with ACSF2 antibodies and how can they be resolved?

When working with ACSF2 antibodies, researchers may encounter several challenges:

• Variable band sizes in Western blot:

  • Issue: ACSF2 may appear between 55-70 kDa rather than at the calculated 68 kDa .

  • Solution: Confirm specificity using knockdown controls. Consider different extraction methods to ensure complete protein solubilization.

• Differential subcellular localization:

  • Issue: ACSF2 localizes to different compartments depending on cell type (Golgi in Neuro2a vs. mitochondria in HepG2) .

  • Solution: Include appropriate subcellular markers in immunofluorescence experiments. Modify fixation conditions based on the expected localization.

• Low signal in immunohistochemistry:

  • Issue: Variable expression levels across tissues.

  • Solution: Optimize antigen retrieval (TE buffer pH 9.0 or citrate buffer pH 6.0) and consider signal amplification methods.

• Cross-reactivity concerns:

  • Issue: Potential cross-reactivity with related ACS family members.

  • Solution: Validate with knockdown controls and use antibodies targeting unique epitopes of ACSF2. Consider predicted reactivity data (e.g., human: 100%, mouse: 86%) .

• Batch-to-batch variability:

  • Issue: Performance differences between antibody lots.

  • Solution: Consider recombinant antibodies that offer "unrivalled batch-to-batch consistency" or validate each new lot against previous standards.

How can researchers ensure reproducible results when using different lots or sources of ACSF2 antibodies?

To ensure reproducible results across different antibody lots or sources:

• Reference sample validation: Maintain a reference positive control sample and test each new antibody lot against this standard.

• Detailed protocol documentation: Record comprehensive details of experimental conditions, including blocking agents, antibody dilutions, incubation times and temperatures.

• Multiple epitope targeting: Use antibodies targeting different epitopes of ACSF2 (N-terminal, C-terminal, internal) to confirm consistent detection patterns .

• Recombinant antibody consideration: Consider using recombinant monoclonal antibodies that offer greater batch-to-batch consistency through standardized production methods .

• Quantitative benchmarking: Establish quantitative standards for antibody performance in your system (e.g., signal-to-noise ratio, minimum detectable concentration).

• Cross-validation: When changing antibody sources, perform parallel experiments with both old and new antibodies to ensure comparable results.

• Antibody characterization data: Review available validation data for each antibody, including predicted reactivity across species and specific validation methods used .

Implementing these practices will help maintain experimental reproducibility when working with ACSF2 antibodies from different sources or production lots.